Meeting
2011 Gastrointestinal Cancers Symposium
Evaluation of progression-free survival by blinded independent central review in patients with progressive, well-differentiated pancreatic neuroendocrine tumors treated with sunitinib or placebo.
Authors
Eric Van Cutsem
University Hospital Gasthuisberg
Eric Van Cutsem , Jean Seitz , Jean-Luc Raoul , Juan Valle , Sandrine Faivre , Shem Patyna , Eric Raymond
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 29: 2011 (suppl 4; abstr 249)
Abstract #
249
Poster Bd #
A97
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET).
First Author: Aaron Vinik
Poster
2017 Gastrointestinal Cancers Symposium
The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors.
First Author: Eric Raymond
Poster
2021 ASCO Annual Meeting
Subgroup analysis by Ki-67 and baseline CgA of the randomized, placebo-controlled phase 3 study of surufatinib in advanced well-differentiated pancreatic neuroendocrine tumors (SANET-p).
First Author: Xianjun Yu